Biologics as treatment options for anaphylaxis. Issue 5 (October 2021)

• Record Type: Journal Article
• Authors: Cafarotti, Arianna; Fiocchi, Alessandro; Arasi, Stefania
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 21:Issue 5(2021)
• Publication Date: 2021-10
• Subjects: allergy severity -- anaphylaxis -- biologics -- omalizumab -- precision medicine; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000779
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: To provide the most recent insights in the use of biologicals in the treatment of patients with anaphylaxis. Recent findings: There is evidence that biologics such as omalizumab may be safe and effective in preventing anaphylactic reactions in patients at high risk mainly because of severe food allergy or desensitization procedures to food, airborne allergen, drugs, or hymenoptera venom. Summary: Further knowledge will guide the adoption and implementation of any new therapy including biologics for anaphylaxis according to the stratification of risk/benefits.